Therapeutics

• trabectedin
  21 February 2017

  WKP
  Definition: Trabectedin (also known as ecteinascidin 743 or ET-743) is an anti-tumor drug. It is sold by Zeltia and Johnson and Johnson under the brand name Yondelis. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is also undergoing clinical trials for the treatment of breast, prostate, and paediatric sarcomas.
  The European Commission and the U.S. Food and Drug Administration (FDA) have granted orphan drug status to (...)

• trifluridine/tipiracil
  21 February 2017

  WKP
  Definition: Trifluridine/tipiracil (trade name Lonsurf) is a combination drug combining trifluridine and tipiracil for the treatment of metastatic colorectal cancer. It is a combination of two active pharmaceutical ingredients: trifluridine, a nucleoside analog, and tipiracil, a thymidine phosphorylase inhibitor. Tipiracil prevents rapid metabolism of trifluridine, increasing the bioavailability of (...)

• trifluridine
  21 February 2017

  WKP
  Definition : Trifluridine (also called trifluorothymidine or TFT) is an anti-herpesvirus antiviral drug, used primarily on the eye. It was sold under the trade name Viroptic by Glaxo Wellcome, now merged into GlaxoSmithKline.
  Trifluridine was approved for medical use in 1980. It is also a component of the anti-cancer drug trifluridine/tipiracil , which is taken by (...)

• panobinostat
  21 February 2017

  WKP
  Panobinostat (trade name Farydak fayr-ah-dak) is a drug by Novartis for the treatment of various cancers. It is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor).
  On 23 February 2015 it received FDA accelerated approval for use in patients with multiple myeloma, and on 28 August 2015 it was approved by the European Medicines Agency for the same (...)

• doxetaxel
  16 February 2017

  Taxotere
  |WKP|
  Definition Docetaxel is of the chemotherapy drug class; taxanes , and is a semi-synthetic analogue of paclitaxel ( Taxol ), an extract from the bark of the rare Pacific yew tree Taxus brevifolia.
  Due to scarcity of paclitaxel, extensive research was carried out leading to the formulation of docetaxel – an esterified product of 10-deacetyl baccatin III, which is extracted from the renewable and more readily available leaves of the European yew (...)

• pemetrexed
  6 November 2014

  Alimta WP
  Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
  Pemetrexed is chemically similar to folic acid and is in the class of chemotherapy drugs called "folate antimetabolites". It works by inhibiting three enzymes used in purine and pyrimidine synthesis—thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide (...)

• enzalutamide
  13 July 2014

  WP
  Enzalutamide (marketed as Xtandi and formerly known as MDV3100) is an androgen receptor antagonist drug developed by the pharmaceutical company Medivation for the treatment of metastatic castration-resistant prostate cancer.
  Medivation has reported up to an 89% decrease in prostate specific antigen serum levels after a month of taking the medicine.
  Early preclinical studies also suggest that enzalutamide inhibits breast cancer cell growth.
  In August 2012, the U.S. Food and Drug (...)

• temozolomide
  4 June 2013

  Temodar and Temodal and Temcad WP
  Temozolomide (brand names Temodar and Temodal and Temcad) is an oral alkylating agent used for the treatment of Grade IV astrocytoma — an aggressive brain tumor, also known as glioblastoma multiforme — as well as for treating melanoma, a form of skin cancer.
  Temozolomide is also indicated for relapsed Grade III anaplastic astrocytoma and not indicated for, but as of 2011 used to treat oligodendroglioma brain tumors in some countries, replacing the (...)

• genome-targeted therapy
  19 April 2010

  See also
  therapy
  therapeutics

• nilotinib
  2 September 2008

  References
  Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880.
  Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-2551.
  Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (...)

0 | 10 | 20 | 30 | 40